ArticleThoracic cancer2025
S- and R-Carvedilol Prevent Benzo(a)pyrene-Induced Lung Carcinogenesis.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S- and R-Carvedilol Prevent Benzo(a)pyrene-Induced Lung Carcinogenesis.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung cancer is the most common and deadly type of cancer. Our previous study showed that carvedilol, a β-blocker, can prevent lung cancer induced by benzo(a)pyrene [B(a)P]. Carvedilol is a 1:1 racemic mixture of S- and R-carvedilol, with S-carvedilol acting as a β-adrenergic blocker, while R-carvedilol lacks β-blocking activity. Despite this, a previous study showed that R-carvedilol effectively prevents UV-induced skin cancer. This study aimed to determine whether carvedilol's lung cancer prevention relies on its β-blocking activity. We compared the effectiveness of S- and R-carvedilol in preventing lung cancer induced by B(a)P and its metabolite, benzo(a)pyrene diol epoxide (BPDE), both in vivo and in vitro. Our results showed that S- and R-carvedilol equally prevent malignant transformation of the human bronchial epithelial cell line (BEAS-2B) induced by BPDE. Furthermore, both S- and R-carvedilol significantly inhibit the B(a)P-induced activation of the aryl hydrocarbon receptor (AhR)/xenobiotic responsive element (XRE) and mRNA expression of CYP1A1 in BEAS-2B cells. In mice, daily administering S- or R-carvedilol for 7 days before exposing them to B(a)P resulted in a significant decrease in the levels of lactate dehydrogenase and malondialdehyde and prevented inflammatory cell infiltration and histopathologic abnormalities in mouse lungs. Exposure to B(a)P caused the development of lung tumors, but treating the mice with S- or R-carvedilol for 23 weeks significantly reduced the number and size of these tumors. The results were confirmed by H&E-stained images of the mouse lungs. These findings support the hypothesis that carvedilol prevents B(a)P-induced lung inflammation and carcinogenesis independently of β-blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.